ImCheck Therapeutics, an Ipsen company
2 clinical trials · Sponsor
◉ Watch ImCheck Therapeutics, an Ipsen company
| Record | Firm | Date |
|---|---|---|
| Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors (NCT05307874) | ImCheck Therapeutics, an Ipsen company | 2022-05-04 |
| First-in-Human Study of ICT01 in Patients With Advanced Cancer (NCT04243499) | ImCheck Therapeutics, an Ipsen company | 2020-03-05 |
Track ImCheck Therapeutics, an Ipsen company automatically
Every clearance here is in the API, with alerts when new ones post.